InsidersTradesSigma
Follow the 瑞康医药 share price and the full management transaction log of the company, a listed issuer based in China. Shares are quoted on the CN market, under the oversight of SSE / SZSE (CSRC). Operating in the Health Care sector, 瑞康医药 has recorded 6 reports. Market capitalisation: €4.1bn. The latest transaction was filed on 21 June 2024 (Purchase). Among the most active insiders: 张仁华. All data is free.
6
Insider Decl.
n/a
Thresholds
€772,687
1 ops.
Buy Volume
€28m
5 ops.
Sell Volume
7Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 25,751 of 29,063 companies
23.5
score / 100
Value29
Quality18
FCF yld-0.3%
Earn yld0.4%
EV/EBITDA24.2x
ROE0.8%
Gross mgn11%
Net mgn0.2%
Debt/EBITDA12.8x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 21 June 2024
Declarations6 total
2,638,600 sharesA股XSHESZSE:173000007779437440
6 of 6 declarations
Acerca de 瑞康医药
瑞康医药 es una empresa especializada en el sector de la salud y farmacéutico, que ofrece productos y servicios relacionados con la atención médica. Cotiza en el mercado XSHE.